Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaccine combo aims to shrink liver tumors in advanced cancer

NCT ID NCT05528952

Disease control Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a cancer vaccine (UCPVax) to standard immunotherapy (atezolizumab and bevacizumab) can shrink tumors better than standard therapy alone in people with advanced liver cancer that cannot be removed by surgery. About 105 adults who have not had prior systemic treatment will participate. The main goal is to see how many patients have their tumors shrink or disappear after 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main inclusion Criteria: 1. Signed informed consent 2. Histologically confirmed hepatocellular carcinoma 3. Locally advanced, metastatic, or unresectable disease 4. Patient who had not previously received systemic anti-cancer treatment 5. Age ≥ 18 years 6. Measurable disease defined according to mRECIST guidelines (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.) 7. Patients who have received previous chemoembolization, radioembolization and/or radiotherapy should have recovered from any treatment related toxicity, to a level of ≤ grade 1 (according to National Cancer Institute \[NCI\] common terminology criteria for adverse events, version 5 (CTCAE v5) with the exception of Grade 2 alopecia 8. Performance status \< 2 9. Child-Pugh Class A status 10. BCLC C stage or BCLC B stage not eligible to loco-regional therapy according to the Barcelona Clinic Liver Cancer (BCLC) staging system Main exclusion Criteria: Non-eligible to a clinical trial: 1. Patients previously exposed to anti-tumor immunotherapy as anti-PD-1, anti-PD-L1, or anti-CTLA4 agent or any immune therapy. 2. Diagnosis of additional malignancy within 3 years prior to the inclusion with the exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical or breast cancer 3. Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study 4. Current participation in a study of an investigational agent or in the period of exclusion 5. Patient under guardianship, curatorship or under the protection of justice Cancer-specific exclusion criteria: 6. Know fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 7. Uncontrolled pleural effusion, pericardial effusion, ascites or symptomatic fistula 8. Uncontrolled tumor-related pain: exposing patients to risk of exposure to corticoids or iterative hospitalizations. Symptomatic lesions amenable to palliative radiotherapy should be treated prior to inclusion. Patients should be recovered from the effects of radiation. There is no required minimum recovery period 9. Known active central nervous system metastases and/or carcinomatous meningitis. Subject with previously treated brain metastases and with radiological and clinical stability are allowed Non-eligible to treatment: 10. History of encephalopathy 11. Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to randomization 12. Inadequate organ functions: known cardiac failure of unstable coronaropathy, respiratory failure, or uncontrolled infection or another life-risk condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CH William Morey

    RECRUITING

    Chalon-sur-Saône, France

  • CH de Mulhouse

    RECRUITING

    Mulhouse, France

  • CHU de Besançon

    RECRUITING

    Besançon, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Poitiers

    NOT_YET_RECRUITING

    Poitiers, France

  • Centre Georges François Leclerc

    RECRUITING

    Dijon, France

  • Centre Hospitalier Paris St Joseph

    NOT_YET_RECRUITING

    Paris, France

  • Groupe Hospitalier Paris Salpetrière

    RECRUITING

    Paris, France

  • Hôpital BEAUJON

    RECRUITING

    Paris, France

  • Hôpital Henri Mondor

    RECRUITING

    Créteil, France

  • Hôpital Nord Franche-Comté

    RECRUITING

    Montbéliard, France

  • Hôpital Paul Brousse

    RECRUITING

    Villejuif, France

  • Institut Mutualiste Montsouris

    RECRUITING

    Paris, France

  • Institut de Cancérologie de l'Ouest

    NOT_YET_RECRUITING

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.